Manufacturer of Controlled Substances; Notice of Application, 14690 [2011-6156]
Download as PDF
<![CDATA[
14690
Federal Register / Vol. 76, No. 52 / Thursday, March 17, 2011 / Notices
Drug
Schedule
Dihydrocodeine (9120) ..................
Oxycodone (9143) .........................
Hydromorphone (9150) ..................
Diphenoxylate (9170) .....................
Ecgonine (9180) ............................
Hydrocodone (9193) ......................
Levorphanol (9220) ........................
Meperidine (9230) ..........................
Methadone (9250) .........................
Methadone intermediate (9254) ....
Metopon (9260) .............................
Dextropropoxyphene, bulk (9273)
Morphine (9300) ............................
Oripavine (9330) ............................
Thebaine (9333) ............................
Opium extracts (9610) ...................
Opium fluid extract (9620) .............
Opium tincture (9630) ....................
Opium, powdered (9639) ...............
Opium, granulated (9640) ..............
Levo-alphacetylmethadol (9648) ...
Oxymorphone (9652) .....................
Noroxymorphone (9668) ................
Alfentanil (9737) .............................
Remifentanil (9739) .......................
Sufentanil (9740) ...........................
Fentanyl (9801) ..............................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Dated: March 8, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–6156 Filed 3–16–11; 8:45 am]
BILLING CODE 4410–09–P
The firm plans to manufacture the
listed controlled substances for internal
use and for sale to other companies.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 16, 2011.
Dated: March 9, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
srobinson on DSKHWCL6B1PROD with NOTICES
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 10,
2010, Cambrex Charles City, Inc., 1205
11th Street, Charles City, Iowa 50616,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
4-Anilino-N-Phenethyl-4-Piperidine
Jkt 223001
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated November 18, 2010,
and published in the Federal Register
on December 3, 2010, (75 FR 75498),
Agilent Technologies, 25200
Commercentre Drive, Lake Forest,
California 92630–8810, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Schedule
Phencyclidine (7471) .....................
1-piperidinocyclohexanecarbonitrile
(8603).
Benzoylecgonine (9180) ................
BILLING CODE 4410–09–P
15:48 Mar 16, 2011
DEPARTMENT OF JUSTICE
Drug
[FR Doc. 2011–6157 Filed 3–16–11; 8:45 am]
VerDate Mar<15>2010
(ANPP) (8333), a basic class of
controlled substance.
The company plans to use this
controlled substance in the manufacture
of another controlled substance.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 16, 2011.
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Agilent Technologies to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Agilent Technologies to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: March 9, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–6163 Filed 3–16–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated November 1, 2010,
and published in the Federal Register
on November 12, 2010, 75 FR 69464,
Noramco Inc., 1440 Olympic Drive,
Athens, Georgia 30601, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Codeine-N-Oxide (9053) ..............
Morphine-N-Oxide (9307) .............
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Carfentanil (9743) .........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
Schedule
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Noramco Inc., to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated
E:\FR\FM\17MRN1.SGM
17MRN1
]]>Agencies
[Federal Register Volume 76, Number 52 (Thursday, March 17, 2011)]
[Notices]
[Page 14690]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-6156]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on September 10, 2010, Cambrex
Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made
application by letter to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of 4-Anilino-N-Phenethyl-4-
Piperidine (ANPP) (8333), a basic class of controlled substance.
The company plans to use this controlled substance in the
manufacture of another controlled substance.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than May 16, 2011.
Dated: March 8, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-6156 Filed 3-16-11; 8:45 am]
BILLING CODE 4410-09-P
